摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,1'-(2,3-吡啶二基)二乙酮 | 16174-40-6

中文名称
1,1'-(2,3-吡啶二基)二乙酮
中文别名
——
英文名称
2,3-Diacetylpyridin
英文别名
Diacetylpyridine;1-(2-acetylpyridin-3-yl)ethanone
1,1'-(2,3-吡啶二基)二乙酮化学式
CAS
16174-40-6
化学式
C9H9NO2
mdl
——
分子量
163.176
InChiKey
IDHCQGUWHXGMQW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    47
  • 氢给体数:
    0
  • 氢受体数:
    3

SDS

SDS:6d59492e74863e3c7fd969c2e723c2d5
查看

反应信息

  • 作为反应物:
    描述:
    N-氨基咔唑1,1'-(2,3-吡啶二基)二乙酮甲酸 作用下, 以 甲醇 为溶剂, 反应 8.0h, 以75.1%的产率得到2,6-diacetylpyridinedicarbazol-N-ylimine
    参考文献:
    名称:
    Catalysts for the polymerization of unsaturated compounds
    摘要:
    Bisimine化合物的化学式(I)中,符号的含义如下:A是从N、S、O和P中选取的非金属,R1是化学式NR5R6的基团,R2是化学式NR5R6或NR7R8、烷基、芳基或环烷基的基团,R5和R6与N原子一起形成一个5、6或7元环,其中一个或多个—CH—或—CH2—基团可被适当的杂原子基团取代,环可以饱和或不饱和、未取代或取代,或与进一步的碳环或杂碳环的5或6元环融合,后者可以饱和或不饱和、取代或未取代,R7和R8是彼此独立的烷基、芳基或环烷基基团,R3、R4是彼此独立的H或烷基、芳基或环烷基基团,n为1或2,用于制备可用于聚合不饱和化合物的双咪唑配合物。
    公开号:
    US20050085527A1
  • 作为产物:
    描述:
    参考文献:
    名称:
    Ozonolysis of Quinolines: A Versatile Synthesis of Polyfunctional Pyridines
    摘要:
    描述了一种简单、安全且高效的程序,易于大规模适应,用于合成取代的喹啉2,这些喹啉在矿物酸存在下可被臭氧迅速氧化,随后进行过氧化氢的氧化处理,得到取代的2,3-吡啶二甲酸3a-d、f和酰基吡啶3e,g。
    DOI:
    10.1055/s-1989-27423
点击查看最新优质反应信息

文献信息

  • Boron-Containing Small Molecules as Anti-Inflammatory Agents
    申请人:ANACOR PHARMACEUTICALS, INC.
    公开号:US20150291629A1
    公开(公告)日:2015-10-15
    Compounds and methods of treating anti-inflammatory conditions are disclosed.
    化合物和治疗抗炎症状况的方法被披露。
  • Homogeneous Dimerization Catalysts Based on Vanadium
    申请人:Lang Julian R.V.
    公开号:US20110071294A1
    公开(公告)日:2011-03-24
    A series of new bis(imino)pyridine vanadium(III) complexes was synthesized according to formula: They were tested for the homogeneous catalytic dimerization of propylene after activation with MAO and showed excellent selectivity for dimerization. The catalysts can be used with or without PPh 3 as an additive to produce ≧80% dimerized alkenes.
    根据公式合成了一系列新的双(亚胺)吡啶钒(III)配合物。这些配合物经MAO活化后用于丙烯的均相催化二聚化反应,表现出优异的二聚选择性。这些催化剂可与或不与PPh3作为添加剂一起使用,产生≧80%的二聚烯烃。
  • Metal-free C–H methylation and acetylation of heteroarenes with PEG-400
    作者:Vishal Suresh Kudale、Jeh-Jeng Wang
    DOI:10.1039/d0gc01183e
    日期:——
    efficient route for methylation and acetylation of aza-heteroarenes using PEG-400 under O2 and TsOH·H2O for the first time by tuning the reaction conditions using a different set of starting materials. The key features of the current protocol are oxidative C–O and C–C bond scission under metal-free conditions with good functional group tolerance, and a broad substrate scope. The potential applicability
    从可再生和廉价来源产生甲基碳来源具有挑战性。在本文中,我们通过使用不同的起始原料调整反应条件,首次描述了在O 2和TsOH·H 2 O下使用PEG-400进行氮杂杂芳烃甲基化和乙酰化的新颖而有效的途径。当前协议的关键特征是在无金属条件下具有良好的官能团耐受性和广泛的底物范围的氧化性C–O和C–C键断裂。通过一锅法证明了所设计方法的潜在适用性,可用于合成中枢神经系统(CNS)抑制剂和抗惊厥药物分子。
  • [EN] TRANSITION METAL COMPLEXES<br/>[FR] TRANSITION METAL COMPLEXES
    申请人:SHELL INT RESEARCH
    公开号:WO2005090371A1
    公开(公告)日:2005-09-29
    A transition metal complex which is a bis-arylimine pyridine MXn complex, comprising a bis-arylimine pyridine ligand having the formula (I), wherein R1-R5, R7-R9, R12 and R14 are each, independently, hydrogen, optionally substituted hydrocarbyl, an inert functional group, or any two of R1-R3 and R7-R9 vicinal to one another taken together may form a ring, and R6 is hydrogen, optionally substituted hydrocarbyl, an inert functional group, or taken together with R7 or R4 to form a ring, R10 is hydrogen, optionally substituted hydrocarbyl, an inert functional group, or taken together with R9 or R4 to form a ring, R11 is hydrogen, optionally substituted hydrocarbyl, an inert functional group, or taken together with R12 or R5 to form a ring, R15 is hydrogen, optionally substituted hydrocarbyl, an inert functional group, or taken together with R14 or R5 to form a ring, provided that R13 and at least one of R12 and R14 are independently selected from optionally substituted C1-C30 alkyl, optionally substituted C4-C30 alkyloxy, halogen and optionally substituted C5-C20 aryl, or R13 taken together with R12 or R14 form a ring, or R12 taken together with R11 form a ring and R14 taken together with R15 form a ring, and provided that at least one of R12, R13 and R14 is optionally substituted C4-C30 alkyloxy; M is a transition metal atom in particular selected from Ti, V, Cr, Mn, Fe, Co, Ni, Pd, Rh, Ru, Mo, Nb, Zr, Hf, Ta, W, Re, Os, Ir or Pt; n matches the formal oxidation state of the transition metal atom M; and X is halide, optionally substituted hydrocarbyl, alkoxide, amide, or hydride. The transition metal complexes of the present invention, their complexes with non-coordinating anions and catalyst systems containing such complexes have good solubility in non-polar media and chemically inert non-­polar solvents especially aromatic hydrocarbon solvents. The catalyst systems can be used for a wide range of (co­)oligomerization, polymerization and dimerization reactions.
    一种过渡金属配合物,为双芳胺吡啶MXn配合物,包括具有化学式(I)的双芳胺吡啶配体,其中R1-R5、R7-R9、R12和R14分别为独立的氢、可选择取代的烃基、惰性官能团,或R1-R3和R7-R9中的任意两个邻位取代基可以形成环,R6为氢、可选择取代的烃基、惰性官能团,或与R7或R4一起形成环,R10为氢、可选择取代的烃基、惰性官能团,或与R9或R4一起形成环,R11为氢、可选择取代的烃基、惰性官能团,或与R12或R5一起形成环,R15为氢、可选择取代的烃基、惰性官能团,或与R14或R5一起形成环,其中R13和至少一个R12和R14独立地选自可选择取代的C1-C30烷基、可选择取代的C4-C30烷氧基、卤素和可选择取代的C5-C20芳基,或R13与R12或R14一起形成环,或R12与R11一起形成环,R14与R15一起形成环,且至少一个R12、R13和R14为可选择取代的C4-C30烷氧基;M为过渡金属原子,特别选自Ti、V、Cr、Mn、Fe、Co、Ni、Pd、Rh、Ru、Mo、Nb、Zr、Hf、Ta、W、Re、Os、Ir或Pt;n与过渡金属原子M的形式氧化态相匹配;X为卤素、可选择取代的烃基、烷氧基、酰胺或氢化物。本发明的过渡金属配合物及其与非配位阴离子的复合物和含有此类配合物的催化系统在非极性介质和化学惰性非极性溶剂中具有良好的溶解性,特别是芳香烃类溶剂。该催化系统可用于广泛的(共)寡聚化、聚合和二聚化反应。
  • METHODS AND COMPOUNDS FOR ENHANCING CONTRAST IN MAGNETIC RESONANCE IMAGING (MRI)
    申请人:Brock University
    公开号:US20160362434A1
    公开(公告)日:2016-12-15
    The present application relates to methods and compounds for enhancing contrast in magnetic resonance imaging. The methods comprise administering compounds of Formula I(a) or I(b) to a subject and obtaining a magnetic resonance image of the subject. The present application also relates to methods of preparing compounds of the Formula I(a) as well as intermediate compounds used in such a method of preparation.
    本申请涉及增强磁共振成像对比度的方法和化合物。该方法包括向受试者注射I(a)或I(b)公式的化合物,并获取受试者的磁共振图像。本申请还涉及制备I(a)公式化合物的方法,以及用于此类制备方法的中间化合物。
查看更多